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ABSTRACT 
Purpose: Blue-blocking (BB) spectacle lenses, which attenuate short-wavelength light, are being 
marketed to alleviate eyestrain and discomfort when using digital devices, improve sleep quality and 
potentially confer protection from retinal phototoxicity. The aim of this review was to investigate 
the relative benefits and potential harms of these lenses. 
Methods: We included randomised controlled trials (RCTs), recruiting adults from the general 
population, which investigated the effect of BB spectacle lenses on visual performance, symptoms of 
eyestrain or eye fatigue, changes to macular integrity and subjective sleep quality. We searched 
MEDLINE, EMBASE, the Cochrane Library and clinical trial registers, until 30 April 2017. Risk of bias 
was assessed using the Cochrane tool. 
Results: Three studies (with 136 participants) met our inclusion criteria; these had limitations in 
study design and/or implementation. One study compared the effect of BB lenses with clear lenses 
on contrast sensitivity (CS) and colour vision (CV) using a pseudo-RCT crossover design; there was no 
observed difference between lens types (log CS; Mean Difference (MD)=-0.01 [-0.03, 0.01], CV total 
error score on 100-hue; MD=1.30 [-7.84, 10.44]). Another study measured critical fusion frequency 
(CFF), as a proxy for eye fatigue, on wearers of low and high BB lenses, pre- and post- a 2-hour 
computer task. There was no observed difference between low BB and standard lens groups, but 
there was a less negative change in CFF between the high and low BB groups (MD=1.81 [0.57, 3.05]). 
Both studies compared eyestrain symptoms with Likert scales. There was no evidence of inter-group 
differences for either low BB (MD=0.00 [-0.22, 0.22]) or high BB lenses (MD=-0.05 [-0.31, 0.21]), nor 
evidence of a difference in the proportion of participants showing an improvement in symptoms of 
eyestrain or eye fatigue. One study reported a small improvement in sleep quality in people with 
self-reported insomnia after wearing high compared to low-BB lenses (MD=0.80 [0.17, 1.43]) using a 
10-point Likert scale. A study involving normal participants found no observed difference in sleep 
quality. We found no studies investigating effects on macular structure or function.  
Conclusions: We find a lack of high quality evidence to support using BB spectacle lenses for the 
general population to improve visual performance or sleep quality, alleviate eye fatigue or conserve 
macular health. 
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INTRODUCTION 
Rationale 
Studies, in animal models1, 2 and cell culture,3, 4 have shown that wavelengths in the blue portion of 
the electromagnetic spectrum (400-500nm) can induce phototoxic retinal damage. Historically, two 
mechanisms of photochemical damage have been recognised and eponymously named as ‘Noell 
damage’ and ‘Ham damage’ after the original investigators.1, 5 Noell, or Class I, damage was first 
observed following prolonged exposure of albino rats to fluorescent light (490-580nm). Cellular 
disruption occurred initially in photoreceptors, followed by the retinal pigment epithelium (RPE). By 
contrast, Ham5 (Class II damage) described disruption that occurred after shorter, high intensity light 
exposures (between 10s and 2h duration). Shorter wavelengths were associated with more intense 
cellular damage, initially at the level of the RPE, with a peak of the action spectrum occurring at 
around 440nm in the phakic eye. International standards have been developed based on these 
empirical studies6, which define exposure limits, below which adverse effects are unlikely to occur. 
However, driven by requirements for brighter and lower energy lighting, the last 10 years has seen 
significant changes in light sources for both commercial and domestic applications, with an increased 
use of compact fluorescent lamps (CFL) and high intensity light-emitting diodes (LEDs). Moreover, 
white-light LEDs (the most common type of LED) have become ubiquitous in backlit displays in 
smartphones and tablet computers. Although the light emitted by these LEDs appears white, their 
emission spectra show peak emissions at wavelengths corresponding to the peak of the blue light 
hazard function. It has been shown that exposure of cultured RPE cells to light equivalent to that 
emitted from mobile display devices causes increased free radical production and reduced cell 
viability.7 This has raised concerns that the cumulative exposure to blue light from such sources may 
induce retinal toxicity and potentially increase the risk of age-related macular degeneration.8 
 
The rationale for the introduction of blue-blocking ophthalmic lenses was to mitigate the risk of 
retinal toxicity by blocking, or attenuating, short wavelength visible light, usually in the range 400nm 
to 500nm. These ophthalmic devices, which include spectacle lenses, contact lenses and intra-ocular 
lenses (IOLs), contain or are coated with dyes that selectively absorb blue and violet light. The choice 
between a conventional ultraviolet (UV) light blocking IOL and a blue-blocking IOL following cataract 
surgery has generated significant debate in the literature in terms of achieving a balance between 
photoreception and photoprotection.9-12 Possible disadvantages of blocking short-wavelength visible 
light transmission include disturbances of colour perception, decreased scotopic sensitivity (leading 
to poorer performance in dim lighting conditions) and disruption of the timing of the circadian 
system.13 Intrinsically photosensitive retinal ganglion cells, which provide photic input to the central 
circadian clock in the suprachiasmatic nucleus, express melanopsin and have an absorption peak at 
approximately 480nm in the blue part of the spectrum.14 
Compared to their intra-ocular counterpart, blue-blocking spectacle lenses have received relatively 
little scientific attention. Standard spectacle lenses generally offer protection against UV (up to 
wavelengths of 380nm) and the adding of a yellow chromophore can also reduce or eliminate blue 
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light transmission. Alternatively, anti-reflection interference coatings can be applied to both the 
anterior and posterior lens surfaces, to selectively attenuate parts of the blue-violet light spectrum 
(415 to 455 nm); this range of wavelengths includes a significant proportion of the blue light hazard 
function15, while the lens remains transparent to other wavelengths of visible light. In addition to 
their putative benefit for retinal protection, blue-blocking spectacle lenses have also been claimed to 
improve sleep quality following the use of electronic devices at night,16 and reduce eye fatigue and 
symptoms of eye strain during intensive computer tasks.17  
A systematic review of the best available research evidence is essential to assess the 
appropriateness of marketing blue-blocking spectacle lenses at the general spectacle wearing 
population. This evaluation will consider both the relative benefits and potential harms of these 
lenses. 
Objectives 
The primary aim of this systematic review is to evaluate the effectiveness of blue-blocking spectacle 
lenses for improving visual performance and reducing visual fatigue. Our secondary aims are to 
assess whether these lenses are effective in maintaining macular health and to determine any 
positive or negative effects on the sleep-wake cycle. The review will attempt to find scientific 
evidence to answer the following questions: 
1. Compared to standard (non blue-blocking) spectacle lenses, do blue-blocking lenses enhance 
visual performance? 
2. Compared to standard spectacle lenses, do blue-blocking lenses improve visual comfort and/or 
reduce symptoms of visual fatigue? 
3. What is the evidence that blue-blocking spectacle lenses provide protection to the macular and 
preserve macular function? 
4. What is the evidence that blue-blocking spectacle lenses disrupt circadian entrainment and affect 
alertness and/or sleep quality? 
 
METHODS 
The protocol for this review was prospectively published on PROSPERO (2017:CRD42017064117) 
Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017064117), 
 
Search strategy 
We conducted searches using the following bibliographic databases: Ovid MEDLINE, Ovid EMBASE, 
PubMed and the Cochrane Library for relevant articles published before May 2017. We did not use 
any date or language restrictions for the bibliographic searches. An example search strategy for one 
of the databases (Ovid MEDLINE) is included in Supplementary File 1. We also scanned the reference 
list of included studies and contacted experts in the field to ask if they were aware of additional 
published or ongoing trials investigating blue-blocking lenses. We searched the PROSPERO database 
for relevant systematic reviews and searched clinical trials registries (Clinical trials.gov and the 
ISRCTN registry) for recently completed or ongoing trials.  
 
Inclusion and exclusion criteria 
We included randomised controlled trials (RCTs) and pseudo-randomised controlled trials, which 
recruited adults, aged 18 years and above, from the general population and compared blue-blocking 
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spectacle lenses to standard spectacles lenses, or any other comparator, where it was possible to 
isolate the effect of the blue-blocking lens for any of our primary or secondary outcomes. We 
defined blue-blocking lenses as those that block or attenuate short wavelength optical radiation 
between 400nm and 500nm. The review team decided post-hoc that this should include 
comparisons between high and low blue-blocking lenses.  
 
The following outcomes were considered: 
 
Primary outcomes: 
• Any measure of visual performance (e.g., logMAR visual acuity, contrast sensitivity, critical 
fusion frequency (CFF), colour discrimination under photopic or mesopic conditions, scotopic 
sensitivity, dark adaptation, stray light and glare sensitivity) conducted during the follow up 
period of the trial. 
• Any measure of visual fatigue or discomfort (e.g., using questionnaires or visual analogue 
scales) conducted during the follow-up period of the trial. 
 
Secondary outcomes: 
• Proportion of eyes with a structural change in the macula using clinical observation, fundus 
photography or optical coherence tomography (OCT) between six and 24 months following 
the start of the intervention. This could include development of early AMD, progression of 
AMD or progression to late stage AMD, as defined by the trial investigators. 
• Objective or subjective assessment of alertness and/or sleepiness. 
• Effect on average macular pigment optical density (MPOD), measured as the proportion of 
eyes that had a significant increase in MPOD at six months.  
• Overall participant satisfaction with blue-blocking lenses (e.g,. using questionnaires or rating 
scales). 
 
 
Adverse effects: 
• Any ocular and systemic adverse effects associated with the intervention, as reported by the 
study authors. 
 
For the evaluation of visual performance and effect of the intervention on alertness and/or sleep 
quality, we included any measure conducted during the follow-up period of the trial. To assess the 
effects of blue-blocking spectacle lenses on macular health or function, studies had to be at least six 
months duration. 
 
Data extraction and analysis 
Following removal of duplicates, two reviewers (JL and CH) independently screened the titles and 
abstracts identified from the bibliographic searches and resolved any discrepancies by discussion 
and consensus. We obtained full-text copies of potentially eligible studies and these were assessed 
by both reviewers to decide whether they met the inclusion criteria. Reasons for exclusion were 
documented at this stage. We used a data extraction form that was developed and piloted for the 
purpose of this review. We collected data on: study design, details of participants, details of 
intervention, methodology, quantitative data on outcomes and funding sources. Data extraction was 
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conducted independently by two reviewers (JL and CH) and any discrepancies resolved by 
discussion. The extracted numerical data was entered into Revman 518 meta-analytical software by 
one reviewer (JL) and this was checked by a second reviewer (CH). 
 
Two review authors (JL and CH) independently assessed the risk of bias in included studies using the 
Cochrane Risk of Bias tool as detailed in Chapter 8 of the Cochrane Handbook.19 We evaluated risk of 
bias using the following bias domains: 
• selection bias (random sequence generation and allocation concealment); 
• performance bias (masking of participants and personnel); 
• detection bias (masking of outcome assessment); 
• attrition bias (incomplete outcome data); 
• reporting bias (selective reporting of outcomes); 
• other bias (funding source, other conflicts of interest). 
Any differences of opinion in risk of bias assessments were resolved by discussion.  
 
Our measure of treatment effect was the risk ratio (RR) for dichotomous outcomes and the mean 
difference (MD) for continuous outcomes, with 95% confidence intervals [CIs]. 
 
By definition, the intervention was applied to the person and therefore the unit of analysis was the 
same as the unit of randomisation. However, where data was presented from both eyes, we 
analysed the data from the right eye only to avoid a unit of analysis error. Insufficient studies were 
available to conduct the planned meta-analysis. However a descriptive summary of the results of the 
included studies has been provided. Publication bias could not be assessed, as there were an 
insufficient number of studies to conduct this analysis. 
 
We assessed the certainty of the evidence using the Grades of Recommendation, Assessment and 
Evaluation (GRADE) Working Group approach,20 using customised software (GRADEpro GDT). One 
reviewer (JL) conducted the initial assessment and this was checked by the other reviewers (CH and 
LD). We considered risk of bias, inconsistency, indirectness, imprecision, and publication bias when 
judging the certainty of the evidence. 
 
RESULTS 
Results of the searches 
The electronic searches yielded 118 references (see Figure 1 for the PRISMA flow diagram). After 19 
duplicates were removed, we screened the remaining 99 references and obtained the full-text 
reports of 15 references for further assessment. Twelve of these17, 21-31 were eliminated (see Table of 
Excluded Studies in Supplementary File 2 and three RCTs that met the a priori criteria for inclusion 
were included in the final analysis (see Characteristics of Included Studies in Supplementary File 3. 
We did not identify any ongoing studies from our searches of the clinical trials registries. 
Characteristics of included studies 
We included three studies in this review.32-34 Two of the studies were conducted in the USA and one 
in Hong Kong.  
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Burkhart and Phelps32 randomised 20 adult volunteers reporting sleep difficulty to wear either 
amber tinted glasses (blocking wavelengths <550nm) or yellow tinted placebo glasses (blocking 
wavelengths <465nm) for 3h prior to sleep. The primary outcome measure was sleep quality as 
determined by sleep diaries, which incorporated a 10-point Likert sleep quality scale. Sleep diaries 
were completed for one week prior to the intervention (baseline) and for two weeks afterwards. 
Leung and co-workers33 conducted a pseudo-randomised controlled trial involving 80 computer 
users from two age cohorts: young adults, 18-30 years, n=40 and middle aged adults 40-55 years, 
n=40. Participants were randomised into one of three groups to assess the performance of two blue-
blocking spectacle lenses (blue-blocking anti-reflection coating and a brown tinted lens) and a 
regular clear control lens, using a crossover design. The primary outcomes were contrast sensitivity, 
using the Mars contrast sensitivity letter chart under standard and glare conditions, and colour 
discrimination using the Farnsworth-Munsell 100-hue test. Following the visual assessment tests, 
participants wore each assigned lens for one month for a minimum of 2h per day. At the end of each 
wearing period, lens performance was subjectively assessed using a 13-item questionnaire. Each 
question was rated on a 1-5 scale (where 1=very unsatisfactory and 5=very satisfactory). 
Lin and co-workers34 recruited 36 adult subjects who were randomised to one of three groups and 
wore either spectacles with low or high blue-blocking lenses or non-blue blocking lenses for a 2 hour 
computer task using a laptop computer. At the end of the task, critical fusion frequency (CFF) was 
assessed and symptoms of eyestrain were evaluated using a 15-item questionnaire. The CFF is the 
lowest level of continuous flicker that is perceived as a steady source of light and a reduction in CFF 
was interpreted as a measure of eye fatigue. 
Risk of bias and certainty of the evidence 
We evaluated the risk of bias in the included studies using the Cochrane risk of bias tool.19 Figures 2 
and 3 present a graph and summary of the risk of bias for the included studies. Overall the studies 
were at an unclear or high risk of bias. We rated two studies32, 34 as having an unclear risk of 
selection bias, since they did not describe the method for random sequence generation or how this 
was concealed. Leung and colleagues33 allocated participants to different sequences of lens wear by 
date of admission and therefore the sequence was non-random and at a high risk of selection bias. 
Given that two of the included studies randomised small numbers of participants,32, 34 there were 
baseline differences in the outcome of interest, which may have affected the results. Although 
attempts were made to mask outcome assessors to the intervention received, it was not possible to 
mask participants due to differences in appearance between the lenses being tested. We judged one 
study34 to be at a high risk of selective reporting bias, due to a failure to report on 2/15 of the 
questions from the symptom questionnaire and no protocol or trial registration was available. Two 
studies32, 33 were judged to be at an unclear risk of selective reporting since either no protocol or trial 
registry entry was available, or in one case the trial was retrospectively registered.33 
We rated the certainty of evidence for each outcome using GRADE (see Table 1).  
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Effects of the intervention 
Primary outcome measures 
Two studies33, 34 randomising 116 participants, provided data on differences in visual performance 
with blue-blocking lenses compared to a clear control lens. Leung et al33 investigated the effect of 
blue-blocking lenses on contrast sensitivity and colour vision using a crossover design. There was no 
evidence of a difference in log contrast sensitivity or total error score on the FM 100-hue test 
between the intervention and control lenses (Table 1). Lin et al34 measured CFF (a proxy measure of 
eye fatigue) before and after a 2-hour computer task. There was no observed difference between 
the low-blocking and no-blocking (clear) lens groups, but there was evidence of a less negative 
change in CFF between the high and low-blocking lens groups indicating less fatigue with computer 
use for the high-block group (Figure 4). 
These studies also compared symptoms of eyestrain for the intervention and control lenses using 
Likert rating scales.33, 34 Leung et al.33 measured symptoms of eyestrain on a 5-point scale after one 
month of wearing low blue-blocking (blue-filtering anti-reflection coating), high blue-blocking 
(brown-tinted) or control (non blue-blocking) lenses. There was no significant difference between 
the intervention and control lenses for either the low blue-blocking lens (Mean difference (MD)= 
0.00 [-0.22, 0.22]) or the high blue-blocking lens (MD=-0.05 [-0.31, 0.21]). Lin et al34 compared 
symptoms related to eye fatigue or eye strain before and after a two hour computer task for 
participants wearing clear (control) lenses or low or high blue-blocking lenses using a 15-item 
questionnaire. Since there was no statistical difference between the low blue-blocking and clear lens 
groups, the study authors pooled the data for the low blue-blocking and clear lens participants and 
compared the symptom scores, after the task, for each question. Statistical differences between 
groups, for each questionnaire item, were then investigated using the Mann-Whitney U test. For the 
current review, we analysed the ordinal data from the 13 questionnaire items reported and 
calculated the proportion of subjects in each group showing a post-task symptomatic improvement 
for each question. The risk ratio (RR) with 95% confidence intervals was calculated for each question 
using Revman18 (Table 2). A significant symptomatic improvement was found for only one question 
‘My eyes feel itchy’ (RR 2.68 [1.32, 5.44]). 
Secondary outcomes 
There was no available data on the proportion of eyes with any structural change in the macula or 
the effect of blue-blocking spectacle lenses on average MPOD. 
Two studies provided data on the subjective assessment of sleep quality. Leung et al.33 found no 
evidence of a difference in sleep quality for low or high blue-blocking lenses compared to control 
lenses for normal participants (low blue-blocking, MD=0.04 [-0.26, 0.18]; high blue-blocking, 
MD=0.00 [-0.23, 0.23]). By contrast, Burkhart and Phelps32 found a small improvement in sleep 
quality in participants wearing high blue-blocking lenses compared to low blue-blocking lenses in 
individuals experiencing sleep-onset or mid-sleep insomnia (MD=0.80 [0.17, 1.43]). 
One study33 reported on the overall performance of blue-blocking lenses. There was no evidence of 
a difference in performance for either low or high blue-blocking lenses compared with control 
lenses. 
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None of the included studies reported on ocular or systemic adverse effects associated with the 
interventions.  
DISCUSSION 
Blue-blocking spectacle lenses, with varying degrees of short-wavelength light attenuation (ranging 
from 10% to 100%), are being marketed at the general population with claims that they can alleviate 
eyestrain and discomfort (particularly when using computers and other digital devices), improve 
sleep quality and possibly confer protection from retinal phototoxicity. The current systematic 
review did not identify any high quality clinical trial evidence to support these claims. Rather, the 
included studies provided evidence, albeit of low certainty, that there was no significant difference 
in relation to the proportion of subjects showing an improvement in symptoms of eyestrain or eye 
fatigue between the intervention (blue-blocking) and control spectacle lenses. This conclusion differs 
from the authors of one of the included studies. Using Likert scales, Lin and colleagues compared 
symptoms in subjects wearing high-blocking lenses to a combined low block/no block group 
following a two hour computer task. They found symptomatic improvement for the high block group 
in 3 of the 15 questionnaire items (pain around/inside the eye , eyes were heavy and the eyes were 
itchy) following the computer task, compared to subjects not wearing high-blocking lenses. 
However, the authors did not indicate whether this analysis was pre-specified or was part of an 
exploratory post-hoc comparison. Furthermore, there was no suggestion that the authors had 
considered the risk of a type I error associated with multiple statistical comparisons.35 For the 
current study we used the analysis plan that was specified prospectively in the review protocol 
(PROSPERO 2017:CRD42017064117). In addition, we also considered that it would be statistically 
more appropriate and clinically more meaningful to present the data from Lin et al34 as a comparison 
of the proportion of subjects showing a post-task symptomatic improvement for each item in the 
questionnaire, given that we do not accept that the questionnaire responses can reasonably be 
considered to fall on a continuous scale. 
Subjective ratings of overall lens performance were reported in one crossover trial in which 80 
participants wore spectacles with low blue-blocking, high blue-blocking or control (clear) lenses for 
four weeks. There was no observed difference in performance ratings between lens types. A parallel 
group RCT reported that high blue-blocking lenses (but not low blue-blocking lenses) produced a less 
pronounced reduction in CFF after a two-hour computer task indicating less visual fatigue. However, 
the clinical significance of this finding is unclear, since CFF has been shown to decline after reading 
irrespective of whether the task is performed on paper or using an e-reader. This suggests that the 
CFF parameter may be independent of blue light exposure.36  
In modern society, computers and other digital electronic devices are ubiquitous in both the 
workplace and domestic environments and given the high number of hours per day that most 
individuals spend viewing small text on electronic devices at short working distances, it is not 
surprising that up to 90% of users periodically experience asthenopic symptoms including, eyestrain, 
headaches, ocular discomfort, dry eye, diplopia and blurred vision.37 However, what is now termed 
computer (or digital) vision syndrome is a multifactorial condition with several potential contributory 
causes, such as uncorrected refractive error, oculomotor disorders, tear film abnormalities and/or 
musculoskeletal problems.38 Therefore, the role played by blue light in these symptoms is difficult to 
extricate. 
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Despite the putative benefits of blue light blocking lenses, concerns have been raised that these 
lenses could adversely affect some aspects of visual performance (e.g., contrast sensitivity or colour 
vision). Using standard clinical tests, Leung et al.33 did not observe any detrimental effects on log-
contrast sensitivity or total error score using the FM 100-hue colour vision test. This is consistent 
with a previous systematic review39 and meta-analysis comparing blue-blocking IOLs with UV-
blocking IOLs, following cataract surgery. The results showed that there was no evidence of any 
difference in post-operative contrast sensitivity or overall colour vision, although colour vision with 
blue-blocking IOLs was impaired at the blue end of the spectrum under mesopic conditions.39 
Given the role of blue light in the timing of the circadian system we examined evidence on the 
influence of blue-blocking lenses on sleep quality. This outcome was reported in two studies. Leung 
and co-workers33 found no observed difference in the effect of either low or high blue-blocking 
lenses on the subjective assessment of sleep quality in normal participants. By contrast, Burkhart 
and Phelps32 recruited participants reporting sleep difficulties who wore either high or low blue-
blocking lenses for three hours prior to sleep for two weeks. High blue-blocking lenses were 
associated with a statistically significant improvement in self-reported sleep quality, based on a 10-
point Likert scale, for the high blue-blocking group compared to the low blue-blocking lens group 
(MD=0.80 [0.17, 1.43]: p=0.03).  
No studies reporting on the effects of blue-blocking spectacle lenses on macular health were 
identified. With the widespread incorporation of backlit LED displays in modern digital devices, 
concerns have been raised regarding the long-term safety of these screens, which have emission 
peaks in the 460nm to 490nm spectral range. One of the suggested benefits of blue-blocking 
spectacle lenses is to protect the retina against these potentially damaging wavelengths. However, 
despite the perceived risks, the spectrally weighted irradiance from these devices does not reach 
international exposure limits, even for prolonged viewing. Moreover, the emissions have been 
shown to be lower than natural exposure from sunlight, even on a cloudy day in winter, in the 
United Kingdom.40  
In summary, the findings of this systematic review indicate that there is a lack of high quality clinical 
evidence for a beneficial effect of blue-blocking spectacle lenses in the general population to 
improve visual performance or sleep quality, alleviate eye fatigue or conserve macular health. Only 
three studies met our inclusion criteria and these were generally poorly reported, with several 
limitations in study design and/or implementation. All three included studies were at risk of 
selection bias; differences in the appearance of the lenses meant that it was impossible to fully mask 
participants to the trial intervention; and we were unable to exclude the possibility of selective 
outcome reporting. We rated the overall certainty of the evidence using GRADE20 as low or very low, 
and therefore we have little to no confidence in the effect estimates. None of the included studies 
reported on adverse effects associated with the use of blue-blocking lenses. 
There is a need for high quality studies to address the effects of blue blocking spectacle lenses on 
visual performance, and the potential alleviation of symptoms of eyestrain and/or visual fatigue. 
There should be an agreed standard set of outcomes, known as ‘core outcome sets’ (COS) as 
recommended by the COMET initiative.41 These sets could then be collected and reported to allow 
the results of studies to be compared and combined as appropriate. The studies investigating these 
outcomes should adopt a RCT design and be conducted on a general population, using blue-blocking 
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lenses with varying degrees of blue light attenuation. Sampling could be stratified to include 
participants varying in age, gender, ethnicity and occupational or domestic exposure to blue light. 
Outcome measures investigated in trials should include those that are important to potential blue-
blocking lens users (e.g., the maintenance of macular health and function, or alleviation of digital 
eyestrain). Furthermore, attempts should be made to mask participants and outcome assessors to 
the intervention, to reduce the risk of performance bias. Finally, given the importance of blue light 
for scotopic sensitivity and in regulating the sleep-wake cycle, the potential harms of blue-blocking 
spectacle lenses should also be considered alongside the putative benefits of these devices. 
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Figure Captions 
Figure 1. Study flow diagram 
Figure 2. Risk of bias graph presented as a % across all included studies 
Figure 3. Risk of bias for included studies 
Figure 4. Comparison of change in Critical Fusion Frequency (CFF), in Hz, before and after a 
computer task for high and low blue-blocking lenses versus control. The high blue-blocking lens is 
associated with a significant change in CFF. Data from the same control group are used in both 
comparisons. 
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Table 1. Results table for primary and secondary outcomes 
Outcome Study Comparison Number of 
participants 
Intervention effect 
 
Certainty 
of Evidence 
(GRADE
20) 
Any measure of visual performance 
conducted during the follow up 
period of the trial. 
Leung 2017 Low blue-block vs clear lens 80 
Log contrast sensitivity (combined 
young and middle aged subjects) 
MD=-0.01 [CI -0.03, 0.01] 
LOW1 
 
Leung 2017 High blue-block vs clear lens 80 
Log contrast sensitivity (combined 
young and middle aged subjects) 
MD=-0.01 [CI -0.03, 0.01] 
Leung 2017 Low blue-block vs clear lens 80 
Colour vision (TES) (combined 
young and middle aged subjects) 
MD=4.03 [CI -4.96, 13.02] 
Leung 2017 High blue-block vs clear lens 80 
Colour vision (TES) (combined 
young and middle aged subjects) 
MD=1.30 [CI -7.84, 10.44] 
Lin 2017 Low blue-block vs clear lens 36 
CFF pre- and post-task 
MD=-0.33 [CI-1.61, 0.95] 
Lin 2017 High blue-block vs clear lens 36 
CFF pre- and post-task 
MD=1.81 [CI 0.57, 3.05] 
 
Any measure of visual fatigue or 
discomfort conducted during the 
follow-up period of the trial. 
Leung 2017 Low blue-block vs clear lens 80 
Relief of eyestrain (combined 
young and middle aged subjects) 
MD=0.00 [CI -0.22, 0.22] 
LOW1 
 
Leung 2017 High blue-block vs clear lens 80 
Relief of eyestrain (combined 
young and middle aged subjects) 
MD=-0.05 [CI-0.31, 0.21] 
Lin 2017 
High blue-block vs not high blue-
block 
36 
Proportion showing an 
improvement in symptoms of 
eyestrain/eye fatigue pre- and 
post-task. ‘My eyes feel tired’ 
19 
 
 
1Downgraded two levels for risk of bias.  2Downgraded one level for indirectness.  
A GRADE certainty of evidence rating of “low” indicates that our confidence in the effect estimate is limited; the true effect may be substantially different 
from the estimate of the effect. A GRADE certainty of “very low” indicates that we have very little confidence in the effect estimate; the true effect is likely 
to be substantially different from the estimate of effect.  
 
Legend: CFF=critical fusion frequency; MD=mean difference; RR=risk ratio; TES=total error score: N/A= not applicable 
RR=3.33 [0.95, 11.66]; ‘I feel pain 
around or inside my eyes’ RR=2.60 
[0.85, 7.98]; ‘My eyes feel heavy’ 
RR=2.50 [0.95, 6.57]. 
 
Objective or subjective assessment of 
alertness/ and/or sleepiness. 
Leung 2017 Low blue-block vs clear lens 80 
Sleep quality (combined young 
and middle aged subjects) 
MD=0.04 [CI -0.26, 0.18] 
VERY 
LOW1,2 
Leung 2017 High blue-block vs clear lens 80 
Sleep quality (combined young 
and middle aged subjects) 
MD=0.00 [CI-0.23, 0.23] 
Burkhart 2009 High blue-block vs low blue-block 20 
Improvement in sleep quality 
MD=0.80 [CI 0.08, 1.52] 
 
Overall participant satisfaction with 
blue-blocking lenses 
Leung 2017 Low blue-block vs clear lens 80 
Overall lens performance  
MD=-0.14 [CI-0.36, 0.08] 
LOW1 
Leung 2017 High blue-block vs clear lens 80 
Overall lens performance  
MD=0.05 [CI -0.17, 0.27] 
 
Proportion of eyes with a structural 
change in the macula following the 
start of the intervention.  
Not reported N/A N/A N/A N/A 
 
Effect on average macular pigment 
optical density (MPOD). 
Not reported N/A N/A N/A N/A 
20 
 
 
Table 2.  Analysis of symptom questionnaire from Lin et al34 comparing subjects wearing high blue 
blocking lenses  to those wearing low blue-blocking or clear lenses . RR=Risk Ratio. 
 Question RR (95%CI) 
I feel pain around or inside my eyes 2.60 [0.85, 7.98] 
My eyes feel heavy 2.50 [0.95, 6.57] 
My eyes feel itchy 2.68 [1.32, 5.44] 
My eyes feel tired 3.33 [0.95, 11.66] 
I find it hard to focus my eyesight 1.75 [0.83, 3.67] 
I see written or computer text as blurry 1.67 [0.54, 5.11] 
My computer monitor looks too bright 1.28 [0.44, 3.67] 
I feel tired when doing work 2.08 [0.74, 5.84] 
My neck shoulders, back and lower back hurt 0.52 [0.13, 2.09] 
My fingers hurt 0.52 [0.07, 4.17] 
I feel mentally stressed 1.30 [0.54, 3.14] 
The suns glare affects my eyes when outdoors 1.37 [0.55, 3.40] 
I find fluorescent office lighting to be bothersome to my eyes 7.00 [0.88, 55.66] 
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Supplementary File 1 
Ovid MEDLINE Search Strategy: 
1. randomized controlled trial.pt.  
2. (randomized or randomised).ab.ti  
3. placebo.ab.ti 
4. drug therapy.fs.  
5. randomly.ab.ti 
6. trial.ab. ti 
7. groups.ab.ti  
8. or/1-7  
9. filtration.sh.  
10. (blue adj2 light$ adj2 filter$).tw.  
11. (blue adj3 filter$).tw.  
12. or/9-12  
13. eyeglasses.sh.  
14. (spectacle$ or glasses).tw.  
15. 13 or 14  
16. 8 and 12 and 15 
See the MEDLINE 2017 Database Guide for a description of search syntax and notation 
http://ospguides.ovid.com/OSPguides/medline.htm 
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Supplementary File 2 
Excluded Studies 
Study Reason for exclusion 
Figueiro 2013 Conference abstract. Not RCT 
Figueiro 2011 Not RCT 
Hovis 1989 Not RCT 
Hammond 2015 Study included pseudophakes only 
Ide 2015 Not RCT 
Kaido 2016 Not RCT 
Lee 2002 Not RCT 
Luria 1972 Not RCT 
Sasseville 2006 No primary/secondary outcomes reported 
Thomas 1988 Not RCT 
Van Der Lely 2015 Not RCT 
Wood 2013  No primary/secondary outcomes reported 
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Supplementary File 3 
Characteristics of Included Studies 
Burkhart & Phelps 2009 
Methods Study aim: to evaluate the effectiveness of blue blocking spectacle lenses to 
improve sleep 
Study design: parallel group RCT 
Participants 
 
Country: USA 
Total number of participants: 20 
Percentage male: 45% 
Average age (SD): 34yrs (8.2) 
Race/Ethnicity: not reported 
Inclusion criteria: subjects experiencing sleep difficulty by subjective account. 
Exclusion criteria: use of any prescribed medication, oral or inhaled nicotine, or 
excessive caffeine use (>2 cups at one time or >500 mg daily). 
Intervention Intervention (n=10): amber-tinted safety glasses (high blue-blocking), which 
blocked wavelengths <550 nm for 3h prior to bedtime 
Comparator (n=10): yellow-tinted safety glasses (low blue-blocking), which 
blocked wavelengths <465 nm for 3h prior to bedtime  
Duration: 3 weeks (1 week baseline assessment and 2 weeks post-intervention) 
Outcomes Primary outcome: sleep quality, determined by a sleep diary which included 
rating of sleep quality using a 10-point Likert scale (0= very poor; 10=very good) 
Secondary outcomes: Mood (positive/negative) determined by the Positive and 
Negative Affect Schedule (PANAS) Mood Scale 
Notes Date conducted: not reported 
Trial registration number: not reported 
Sources of funding: none 
Declaration of interest: authors reported no conflicts of interest 
Risk of bias 
Risk of Bias Domain 
Authors’ 
Judgement Support for judgement 
Adequate sequence 
generation 
Unclear Not reported 
Allocation concealment Unclear Not reported 
Similar baseline 
outcome 
measurements 
High Quote: ‘As shown in Figures 2 and 3, the two groups were not 
equivalent on self-reported baseline quality of sleep (t[18] = 
15.81, p < .001) or self-reported baseline positive affect (t[18] 
= 9.75, p < .001).’ p1607 
Similar baseline 
characteristics 
Low Judgement comment: participants balanced for age, time to 
bed and rising time. By self-report, neither group used 
nicotine, consumed more than 300 mg of caffeine or more 
than 3 oz. of alcohol/day, or used street drugs. 
Incomplete outcome 
data addressed 
Low No missing data 
Adequate blinding 
(participants) 
Low Quote: ‘Participants were asked whether they had knowledge 
of glasses that were designed to improve one's sleep. All 
indicated they had no knowledge.’  p1606 
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Quote: ‘They were also instructed to refrain from researching 
lenses designed to improve sleep and contacting other 
participants to compare the effects of their glasses.’ p1606 
Judgement comment: although the amber and yellow lenses 
could be distinguished the subjects were masked to the study 
hypothesis 
Adequate blinding 
(investigators/outcome 
assessors) 
Unclear Not reported 
Protected against 
contamination 
Low Judgement comment: it is unlikely that contamination 
occurred 
Free of selective 
reporting 
High Judgement comment: no registered trial protocol and the 
results of two questions from the 15-item eyestrain symptom 
questionnaire 
Free from other bias Low Judgement comment: no evidence of other source of bias 
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Leung, Li & Kee 2017 
Methods Study aim: to evaluate the optical performance of blue-light blocking spectacle 
lenses and to investigate whether a reduction in blue light transmission affects 
visual performance and sleep quality. 
Study design: pseudo-randomised cross-over trial 
Participants 
 
Country: Hong Kong 
Total number of participants: 80 
Percentage male: not reported 
Average age (SD): 35.5yrs (12.3) 
Race/Ethnicity: not reported 
Inclusion criteria: aged over 18 years with a refractive error 
Exclusion criteria: best corrected visual acuity worse than LogMAR 0 in either 
eye, history of ocular diseases or ocular surgery or abnormal colour vision based 
on the Ishihara colour vision test 
Intervention Intervention 1 (n=80): blue-filtering anti-reflection (AR) coated lens 
Intervention 2 (n=80): brown-tinted lens 
Comparator (n=80): regular clear anti-reflection coated lens 
Duration: 3 months  (1 month using each of the three lenses) 
Outcomes Primary outcome: contrast sensitivity under normal and glare conditions using 
the Mars contrast sensitivity letter chart and colour discrimination using the 
Farnsworth-Munsell 100-hue test 
Secondary outcomes: subjective lens performance using a 13-item questionnaire 
(including overall performance and questions relating to night vision, sleep 
quality, colour contrast, eyestrain, vision on computers or mobile devices) 
Notes Date conducted: July 2014 to May 2015 
Trial registration number: NCT02821403 (retrospectively registered) 
Sources of funding: Swiss lens laboratory Ltd 
Declaration of interest: part of the funding for the research was charged as 
consultancy by members of the research team 
Risk of bias 
Risk of Bias Domain 
Authors’ 
Judgement Support for judgement 
Adequate sequence 
generation 
High Quote: ‘The sequence of lens types was pseudo-randomized 
for each individual, i.e., participants were allocated in different 
sequences of lens wear by the date of admission.’ p5 
Comment: non-random sequence generation 
Allocation concealment High Judgement comment: non-random predictive sequence 
Similar baseline 
outcome measurements 
Low Judgement comment: cross-over trial and therefore baseline 
outcome measurements balanced 
Similar baseline 
characteristics 
Low Judgement comment:  cross-over trial and therefore baseline 
characteristics balanced 
Incomplete outcome 
data addressed 
Low Judgement comment: No missing data for any of the reported 
outcomes 
Adequate blinding 
(participants) 
High Quote: ‘We controlled subjective bias by allocating the lenses 
in a pseudo-random sequence with their identities masked, 
although the slight tinted appearance of the BT lens might 
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have been easier to identify.’ p12 
Judgement comment: participants were aware of the 
difference between the clear lens and brown tinted lens and 
possibly between the blue filtering AR coat and the clear lens 
for the subjective outcomes  
Adequate blinding 
(investigators/outcome 
assessors) 
High Quote: ‘In the second study, a single-masked pseudo-
randomized controlled clinical trial was conducted to evaluate 
whether blue-light filtering spectacle lenses affected visual 
performance and sleep quality. A double-masked study as 
originally planned was not possible because an investigator 
could differentiate the three lenses due to prior experience in 
ophthalmic dispensing.’ p3 
Protected against 
contamination 
Low Judgement comment: it is unlikely that contamination 
occurred 
Free of selective 
reporting 
Unclear Quote: ‘We registered this study retrospectively at 
ClinicalTrials.gov after we were reminded that our study 
design indeed met the WHO's definition of a clinical trial.’ p5 
Judgement comment: trial retrospectively registered and not 
possible to assess 
Free from other bias High Judgement comment: no attempt to control for potential 
carry over-effects 
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Lin, Gerratt, Bassi & Apte 2017 
Methods Study aim: to determine whether North American subjects who wear short 
wavelength light-blocking glasses during a 2-hour computer task exhibit less 
visual fatigue and report fewer symptoms of visual discomfort than subjects 
wearing glasses with clear lenses. 
Study design: parallel group RCT 
Participants 
 
Country: USA 
Total number of participants: 36 
Percentage male: 55.5% 
Average age (SD): 24.3yrs (1.90) 
Race/Ethnicity: Caucasian (92%), African-American (3%) Asian (4%) 
Inclusion criteria: healthy (no known significant health, problems) volunteer, 
being male or female of any ethnic group, between 21-39 years of age, having 
uncorrected vision or contact lens–corrected vision of 20/30 or better with both 
eyes open, not having performed VDT work for at least 1 hour before testing, and 
not having known visually significant ophthalmic pathology, such as cataracts, 
macular degeneration, glaucoma, eye surgeries, or injuries based on self-
reported history.  
Exclusion criteria: <21 or >40 years of age; had uncorrected vision or contact 
lens–corrected vision worse than 20/30 with both eyes open; self-reported a 
concurrent eye injury or disease; had photosensitivity, which would preclude 
them from comfortably performing 2 hours of VDT work; had been diagnosed 
with epilepsy; or had previously suffered a seizure. 
Intervention Intervention 1 (n=12): low blue-blocking lens (25% blue light blocking) 
Intervention 2 (n=12): High blue-blocking lens (60% blue light blocking 
Comparator (n=12): regular clear lens 
Duration: 2 hour computer task.  
Outcomes Primary outcome: pre- and post-task critical fusion frequency (CFF) 
Secondary outcomes: symptoms of eyestrain using a 15-item questionnaire 
Notes Date conducted: not reported 
Trial registration number: not reported 
Sources of funding: JIN CO LTD 
Declaration of interest: two of the authors were employed by the spectacle lens 
manufacturer (JIN CO LTD) 
Risk of bias 
Risk of Bias Domain 
Authors’ 
Judgement Support for judgement 
Adequate sequence 
generation 
Unclear Not reported 
Allocation concealment Unclear Not reported 
Similar baseline 
outcome measurements 
High Quote: ‘Although we randomly assigned subjects to each of 
the three lens groups, we observed a statistically significant 
difference in baseline CFF when comparing subjects assigned 
to each of the lens groups (F2,33=6.827, P<0.003): subjects in 
the high-block group had lower baseline CFF compared to 
subjects in the low-block group (P<0.002). These findings 
suggested that confounding variables may affect our results.’ 
p444 
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Similar baseline 
characteristics 
Low Quote: ‘There were no differences among the three groups 
based on sex or race/ethnicity (Table 1). Although subjects 
were randomized to each lens group, post hoc testing revealed 
that there was a statistically significant difference between 
the ages of the subjects randomly assigned to the no-block 
and low block groups (P =0.024), but no statistically significant 
differences in age (P > 0.05) between any other pairs of groups 
(Table 1). Furthermore, there were no differences between the 
groups with regard to their average number of hours of sleep 
per night, their average weekly computer use, or whether they 
wore contact lenses (Table 1).’p444-5 
Judgement comment: baseline difference in age of subjects 
was very small 
Incomplete outcome 
data addressed 
Low Judgement comment: No missing data for any of the reported 
outcomes 
Adequate blinding 
(participants) 
High Quote: ‘We cannot rule out the possibility that the subjects 
themselves may have noticed the visual appearance of their 
glasses. Although the control eyeglasses with the no-block 
lenses were constructed in a way to make them as similar as 
possible to the eyeglasses with low- and high-block lenses, the 
high-blocking lenses have a brown color, and the low-blocking 
lenses have a subtle blue-light reflection especially when 
viewed under the light, making it impossible to completely 
mask the subjects.’ p446-7 
Quote: ‘Although study subjects did not wear the eyeglasses 
during the CFF measurements to ensure study personnel were 
masked to group assignments, we cannot rule out the 
possibility that the subjects themselves may have noticed the 
visual appearance of their glasses.’ p446 
Adequate blinding 
(investigators/outcome 
assessors) 
Low Quote: ‘Since the blocking lenses can be identified potentially 
by their tint/color, the manufacturer packaged the eyeglasses 
in opaque boxes that were marked with only a serial number 
to permit proper randomization.’p443-4 
Quote: ‘Although study subjects did not wear the eyeglasses 
during the CFF measurements to ensure study personnel were 
masked to group assignments, we cannot rule out the 
possibility that the subjects themselves may have noticed the 
visual appearance of their glasses.’ p446 
Protected against 
contamination 
Low Judgement comment: it is unlikely that contamination 
occurred 
Free of selective 
reporting 
Unclear Judgement comment: trial not registered and therefore not 
possible to assess 
Free from other bias high Judgement comment: two of the co-authors were employed 
by the company manufacturing the blue blocking lenses 
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